Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics Indian Medical PG Practice Questions and MCQs

Question 461: What is the half-life of nicotine in blood?

A. 2 hours (Correct Answer)
B. 15 minutes
C. 5 hours
D. 24 hours

Explanation: ***2 hours*** - Nicotine has a **relatively short half-life** in the blood, typically around 2 hours, contributing to frequent dosing in tobacco users. - This rapid elimination means that nicotine concentrations decrease significantly within a few hours after the last dose, leading to **withdrawal symptoms** or cravings. *15 minutes* - A 15-minute half-life would imply an **extremely rapid clearance**, which is not characteristic of nicotine. - Such quick elimination would make it very difficult to maintain consistent drug levels and would lead to immediate, intense withdrawal. *5 hours* - While longer than the actual half-life, 5 hours is still within the realm of substances requiring **multiple daily doses**. - However, it would mean nicotine levels would remain elevated for a longer period than observed, potentially delaying withdrawal. *24 hours* - A 24-hour half-life would mean nicotine would accumulate significantly in the body with daily use, leading to **prolonged effects** and a much slower decline in concentrations after cessation. - This half-life is typical for drugs designed for **once-daily dosing**, which is not the case for nicotine.

Question 462: Which of the following statements about transdermal drug delivery systems is false?

A. Applied to chest, abdomen and back
B. Drug is delivered at a constant rate
C. Fentanyl is used
D. Good option in emergency situations (Correct Answer)

Explanation: ***Option D: Good option in emergency situations*** - Transdermal drug delivery systems have a **slow onset of action** due to the time required for drug absorption through the skin layers. - This characteristic makes them **unsuitable for emergency situations** where immediate therapeutic effect is critical for patient stabilization. - Emergency situations require drugs with **rapid onset** via routes like intravenous, intramuscular, or sublingual administration. *Option A: Applied to chest, abdomen and back* - This statement is TRUE. Transdermal patches are commonly applied to areas with **good blood supply** and **minimal hair**, such as the chest, abdomen, and back. - These sites provide a relatively **large surface area** for absorption and allow for discreet placement with consistent drug delivery. *Option B: Drug is delivered at a constant rate* - This statement is TRUE. A primary advantage of transdermal systems is their ability to provide **controlled and sustained release** of medication over an extended period (typically 24-72 hours). - This constant delivery helps maintain **steady-state therapeutic drug levels** and minimizes fluctuations in plasma concentration, reducing side effects. *Option C: Fentanyl is used* - This statement is TRUE. **Fentanyl** is a potent opioid commonly delivered via transdermal patches for **chronic pain management**. - Its transdermal formulation ensures **continuous analgesia** over 72 hours and bypasses first-pass metabolism, improving bioavailability and making it effective for long-term use.

Question 463: Among the following statins, which has the longest half-life?

A. Pravastatin
B. Simvastatin
C. Lovastatin
D. Rosuvastatin (Correct Answer)

Explanation: **Rosuvastatin** - **Rosuvastatin** has the longest half-life among the commonly used statins, approximately **19 hours**, allowing for consistent lipid-lowering effects. - Its prolonged presence in the body contributes to its effectiveness in reducing **LDL-C** at lower doses. *Pravastatin* - **Pravastatin** has a relatively short half-life of about **1.8 hours**, requiring daily dosing to maintain therapeutic concentrations. - Its hydrophilic nature means it is less likely to penetrate non-hepatic tissues, potentially reducing extrahepatic side effects. *Simvastatin* - **Simvastatin** has a short half-life of about **3 hours**, necessitating daily administration. - It is a **prodrug** that requires hepatic activation to its active beta-hydroxy acid form. *Lovastatin* - **Lovastatin** also has a short half-life, around **3 hours**, and is a **prodrug** like simvastatin. - It is often recommended to be taken in the evening due to the diurnal rhythm of cholesterol synthesis.

Question 464: Which of the following statements about oral iron preparations is correct?

A. Most commonly used preparation is ferrous gluconate
B. Ferrous fumarate is most efficient
C. Ferric preparations are more effective
D. Different preparations have different bioavailability (Correct Answer)

Explanation: ***Different preparations have different bioavailability*** - The **bioavailability** of oral iron preparations varies depending on the specific salt used, its formulation, and the presence of absorption enhancers or inhibitors. - This difference in absorption impacts the required dose and efficacy in treating **iron deficiency anemia**. *Most commonly used preparation is ferrous gluconate* - **Ferrous sulfate** is the most commonly prescribed and cost-effective oral iron preparation due to its high iron content and good bioavailability. - While ferrous gluconate is used, its iron content is lower than ferrous sulfate, making it less frequently the primary choice. *Ferrous fumarate is most efficient* - While **ferrous fumarate** has a high elemental iron content, its efficiency doesn't necessarily surpass that of ferrous sulfate or other preparations when considering factors like bioavailability and side effect profile. - **Ferrous sulfate** is often considered efficient due to its balance of elemental iron content, bioavailability, and cost-effectiveness. *Ferric preparations are more effective* - **Ferrous (Fe2+)** iron is generally better absorbed than **ferric (Fe3+)** iron, as ferric iron needs to be reduced to its ferrous form before absorption. - Unless specifically formulated for enhanced absorption (e.g., ferric maltol), ferric preparations are typically *less* effective for initial iron repletion.

Question 465: Which of the following is not excreted by the kidney?

A. Ciprofloxacin
B. Ofloxacin
C. Moxifloxacin (Correct Answer)
D. Levofloxacin

Explanation: ***Moxifloxacin*** - Moxifloxacin is primarily metabolized in the **liver** and excreted through bile and feces. - This characteristic makes it a suitable choice for patients with significant **renal impairment** as dose adjustments are generally not required. *Ciprofloxacin* - Ciprofloxacin is predominantly excreted by the **kidneys** through both glomerular filtration and tubular secretion. - Dose adjustments are crucial in patients with **renal dysfunction** to prevent accumulation and toxicity. *Ofloxacin* - Ofloxacin is largely excreted unchanged in the **urine**, making renal excretion its primary elimination pathway. - **Dose reduction** is necessary for patients with impaired renal function. *Levofloxacin* - Levofloxacin is primarily eliminated via **renal excretion**, with a significant portion appearing in the urine as unmetabolized drug. - Patients with **kidney disease** require appropriate dose adjustments.

Question 466: Which of the following drugs is NOT metabolized by acetylation?

A. Dapsone
B. Metoclopramide (Correct Answer)
C. Procainamide
D. INH

Explanation: ***Metoclopramide*** - **Metoclopramide** is eliminated primarily via renal excretion, with a smaller portion undergoing glucuronidation and sulfation, not acetylation. - Its metabolic pathway does not involve the enzyme **N-acetyltransferase**, which is responsible for acetylation. *Dapsone* - **Dapsone** undergoes significant **N-acetylation** by NAT2 (N-acetyltransferase 2), which is important for its metabolism and clearance. - Genetic variations in NAT2 can lead to individual differences in **dapsone acetylation rates**, affecting drug efficacy and toxicity. *Procainamide* - **Procainamide** is primarily metabolized by N-acetyltransferase 2 (NAT2) to **N-acetylprocainamide (NAPA)**, an active metabolite. - Differences in **acetylation phenotype** (slow vs. rapid acetylators) influence the metabolism of procainamide and the risk of drug-induced lupus. *INH* - **Isoniazid (INH)** is extensively metabolized in the liver, primarily by **N-acetylation** via the enzyme N-acetyltransferase 2 (NAT2). - The rate of INH acetylation varies significantly among individuals, classifying them as **slow or rapid acetylators**, which impacts drug toxicity and efficacy.

Question 467: Which of the following statements represents the most clinically significant aspect of drug metabolism?

A. Most common enzyme involved is CYP 3A4/5 (Correct Answer)
B. Glucuronidation is a phase II reaction
C. Reduction is a phase I reaction
D. Cytochrome P450 is involved in phase I reactions

Explanation: ***Most common enzyme involved is Cyp 3A4/5*** - CYP3A4/5 is the **most abundant and clinically significant** cytochrome P450 enzyme, responsible for metabolizing approximately **50% of all clinically used drugs**. - Its widespread involvement means variations in its activity (due to **genetics, drug interactions, or disease**) have a major impact on drug efficacy and toxicity. *Glucuronidation is a phase II reaction* - While correct that glucuronidation is a **Phase II metabolic reaction**, this statement describes a biochemical classification rather than a clinically significant aspect compared to the involvement of CYP3A4/5. - Phase II reactions generally involve **conjugation** to increase water solubility and facilitate excretion, but they do not collectively account for as many drug interactions as CYP3A4/5 alone. *Reduction is a phase I reaction* - This statement is factually correct as **reduction** is indeed a **Phase I metabolic reaction**. - However, it represents a generic classification of a metabolic pathway and doesn't highlight the specific clinical importance or prevalence of a particular enzyme or reaction in drug metabolism. *Cytochrome P450 is involved in phase I reactions* - This is true; the **cytochrome P450 system** is the primary enzyme system for **Phase I metabolism**, which introduces or exposes polar groups to make drugs more reactive. - While fundamentally important, this statement is too broad; it does not specify the most clinically significant *aspect* or *enzyme* within the P450 system compared to directly identifying CYP3A4/5.

Question 468: Which is the longest acting anti-cholinesterase?

A. Pyridostigmine
B. Ambenonium
C. Edrophonium
D. Echothiophate (Correct Answer)

Explanation: ***Echothiophate*** - **Echothiophate** is an **organophosphate** compound that irreversibly inhibits acetylcholinesterase, leading to a prolonged duration of action, often measured in weeks. - Due to its **long-acting** and irreversible nature, it is primarily used in ophthalmic preparations for glaucoma but is not commonly used systemically. *Pyridostigmine* - **Pyridostigmine** is a medium-acting anticholinesterase, typically lasting **3-6 hours**, and is commonly used for the chronic management of **myasthenia gravis**. - Its effects are **reversible**, binding to the enzyme for a limited period. *Ambenonium* - **Ambenonium** has a longer duration of action than pyridostigmine, typically lasting **4-8 hours**, but is still considered a reversible inhibitor. - It was historically used for **myasthenia gravis** but is now less common due to the availability of other effective treatments. *Edrophonium* - **Edrophonium** is a very short-acting anticholinesterase, with effects lasting only **5-15 minutes**, making it ideal for the **Tensilon test** to diagnose myasthenia gravis and differentiate between myasthenic and cholinergic crises. - Its rapid onset and brief duration are due to its **reversible** and transient binding to acetylcholinesterase.

Question 469: Volume of distribution of a drug is 500 ml and target concentration of drug in blood is 5 g/L. 20% of administered drug is reached to systemic circulation. What will be the loading dose of that drug -

A. 1 gm
B. 5 gm
C. 25 gm
D. 12.5 gm (Correct Answer)

Explanation: ***12.5 gm*** - The formula for loading dose (LD) is: LD = (Target Concentration × Volume of Distribution) / Bioavailability. - Given: Target Concentration = 5 g/L, Volume of Distribution = 500 mL = 0.5 L, Bioavailability = 20% = 0.2. - So, LD = (5 g/L × 0.5 L) / 0.2 = 2.5 g / 0.2 = **12.5 g**. *1 gm* - This value would be obtained if the target concentration was 2 g/L with 100% bioavailability, or if the calculation incorrectly handled the volume or bioavailability factor. - It does not account for the specified **bioavailability of 20%** or the given target concentration and volume of distribution. *5 gm* - This result would be obtained if the bioavailability was assumed to be 50% (LD = 2.5 g / 0.5 = 5 g), or if the volume of distribution was incorrectly used in the calculation. - This option does not correctly factor in the **20% bioavailability** of the administered drug. *25 gm* - This value would result from mistakes such as dividing by bioavailability of 10% instead of 20% (LD = 2.5 g / 0.1 = 25 g), or by multiplying bioavailability instead of dividing by it. - This answer significantly **overestimates** the required dose, which could lead to drug toxicity.

Question 470: Regarding the concepts of efficacy and potency of a drug, which of the following statements is FALSE?

A. ED50 of the drug corresponds to efficacy (Correct Answer)
B. Drugs that produce a similar pharmacological effect can have different levels of efficacy
C. In a clinical setup, efficacy is more important than potency
D. In the log dose response curve, the height of the curve corresponds with efficacy

Explanation: ***ED50 of the drug corresponds to efficacy*** - **ED50** (median effective dose) is the dose at which 50% of individuals exhibit the specified effect; it quantifies **potency**, not efficacy. - **Efficacy** refers to the maximum effect a drug can produce, while potency refers to the amount of drug needed to produce an effect. *In a clinical setup, efficacy is more important than potency* - **Efficacy** determines the maximal therapeutic benefit a drug can achieve for a patient, making it crucial for clinical outcomes. - While **potency** influences the dose required, a highly potent drug that is not very efficacious may not be clinically useful. *Drugs that produce a similar pharmacological effect can have different levels of efficacy* - Two drugs might act on the same receptor but elicit different maximal responses, indicating varying **efficacy**. - For example, a **partial agonist** and **full agonist** interacting with the same receptor will have different efficacies. *In the log dose response curve, the height of the curve corresponds with efficacy* - The **maximal response** or plateau of the dose-response curve represents the **efficacy** of a drug. - A higher plateau on the curve indicates a drug with greater intrinsic activity achieving a larger effect.

Practice by Chapter

Absorption and Bioavailability

Practice Questions

Drug Distribution and Protein Binding

Practice Questions

Biotransformation and Metabolism Pathways

Practice Questions

Renal and Non-renal Excretion

Practice Questions

Compartment Models

Practice Questions

Dose-Response Relationships

Practice Questions

Drug Efficacy and Potency

Practice Questions

Drug Tolerance and Tachyphylaxis

Practice Questions

Population Pharmacokinetics

Practice Questions

Pharmacokinetic Variability

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free